The TRIUMPH-2 retatrutide trial provides phase 3 evidence about body-weight changes and glycaemic control in adults living with obesity and type 2 diabetes.
Published in The Lancet in September 2026, the study examined 1,152 participants over 80 weeks. Its findings are particularly relevant because type 2 diabetes can influence weight-management outcomes, making this population scientifically distinct from participants without diabetes.
The trial reported substantial average reductions in body weight alongside improvements in glycated haemoglobin (HbA1c). However, the findings need to be understood through the study’s design, endpoints and safety observations.
What Was the TRIUMPH-2 Clinical Trial?
TRIUMPH-2 was a randomised, double-blind, placebo-controlled phase 3 trial registered as NCT05929079.
Researchers enrolled adults with obesity or overweight and type 2 diabetes. Participants were assigned to three retatrutide treatment groups or placebo.
At baseline, the participants had an average body mass index (BMI) of 38.2 kg/m² and an average HbA1c of approximately 7.7%.
Most participants were already receiving oral glucose-lowering medicines, meaning the study examined retatrutide within a population receiving established diabetes care rather than exclusively among people without background treatment.
The study’s 80-week duration allowed researchers to assess sustained changes in body weight, glycaemic measurements and reported adverse events during the observation period.
What Was the Primary Endpoint in TRIUMPH-2?
The principal endpoint was the percentage change in body weight from baseline to week 80.
This distinction matters because TRIUMPH-2 included participants with type 2 diabetes, but its primary objective was not simply to measure blood glucose reduction.
Glycaemic outcomes, including changes in HbA1c, were also evaluated.
HbA1c reflects average blood glucose exposure over approximately the preceding two to three months. It is widely used in diabetes research, although individual results can be influenced by factors affecting red blood cells.
The trial therefore provides information about both weight-related and glycaemic outcomes, while retaining a defined primary statistical objective.
What Body-Weight Changes Were Reported?
The peer-reviewed publication reported the following mean percentage changes at week 80 using the treatment-regimen estimand.
| Trial group | Mean body-weight change |
|---|---|
| Retatrutide 4mg | −11.9% |
| Retatrutide 9mg | −16.8% |
| Retatrutide 12mg | −18.8% |
| Placebo | −5.1% |
The estimated differences compared with placebo were statistically significant across the three retatrutide groups.
These figures describe average outcomes in the trial, not the response of every participant.
They also depend on the statistical approach used. The treatment-regimen estimand considers outcomes in the context of treatment discontinuation and other events specified in the study’s analysis plan.
Readers may encounter different percentages in company presentations using an efficacy estimand. Those figures should not be combined with the treatment-regimen results without explaining the difference.
The trial-group quantities above identify published research comparisons only; they are not dosing recommendations.
What Did TRIUMPH-2 Report About HbA1c?
Glycaemic control was an important secondary area of assessment.
The study reported average HbA1c reductions of approximately 1.4 to 1.6 percentage points across the retatrutide groups, compared with approximately 0.2 percentage points for placebo in the corresponding efficacy analysis.
These findings indicate changes in average glycaemic measurements during the trial.
However, an HbA1c reduction should not be interpreted as evidence that type 2 diabetes has been permanently reversed.
HbA1c is a measurement of glycaemic control. Long-term disease progression, treatment withdrawal and complications require additional evidence.
It is also important to distinguish changes in HbA1c from changes in body weight. Although both outcomes may improve within the same trial, they measure different biological and clinical characteristics.
Why Is TRIUMPH-2 Different From TRIUMPH-1?
Both studies belong to the retatrutide phase 3 clinical development programme, but they examined different participant populations.
TRIUMPH-1 studied adults with obesity without diabetes and included specific groups with knee osteoarthritis or obstructive sleep apnoea.
TRIUMPH-2 examined adults with obesity or overweight and established type 2 diabetes.
These differences matter when interpreting the reported weight changes.
Participant characteristics, background medicines, eligibility criteria and statistical analyses can all influence outcomes.
Consequently, comparing the headline percentages from the two trials does not establish how retatrutide would perform in a direct comparison between these populations.
For a detailed discussion of the earlier study, read What Does the Published TRIUMPH-1 Retatrutide Trial Establish?.
What Adverse Events Were Reported?
Gastrointestinal adverse events were the most frequently reported events in TRIUMPH-2.
Diarrhoea was reported in approximately 27–34% of participants across the retatrutide groups, compared with 13% in the placebo group.
Nausea occurred in approximately 14–28% of participants receiving retatrutide, compared with 8% receiving placebo.
The published study also reported hypotension and dysaesthesia more frequently in retatrutide groups than in the placebo group.
Permanent treatment discontinuation due to adverse events or death occurred in 4%, 12% and 8% of the three retatrutide groups, respectively, compared with 5% for placebo.
These findings illustrate why trial interpretation should consider adverse-event frequency and treatment discontinuation alongside efficacy measurements.
The study’s observation period cannot exclude uncommon or longer-term risks.
What Does TRIUMPH-2 Establish About Retatrutide’s Mechanism?
Retatrutide acts at GLP-1, GIP and glucagon receptors.
These receptor systems participate in metabolic regulation, including glucose-dependent signalling and energy balance.
However, the clinical outcomes in TRIUMPH-2 reflect the combined pharmacological activity of the compound.
The trial does not independently determine the proportion of weight reduction or HbA1c change attributable to each receptor.
Laboratory experiments can examine receptor activation more directly.
For example, How Do cAMP Assays Measure Retatrutide Receptor Activation? explains one method used to measure functional receptor signalling.
The related article How Is Retatrutide Receptor Potency Measured Using EC50? examines concentration–response measurements.
Neither laboratory assay can independently establish the clinical outcomes observed in TRIUMPH-2.
What Are the Main Limitations of TRIUMPH-2?
TRIUMPH-2 provides evidence from a large, controlled clinical trial, but several questions remain.
Its findings apply most directly to participants resembling the enrolled population. Outcomes may differ in people with substantially different clinical characteristics.
The 80-week study period also limits conclusions about longer-term safety and the durability of observed effects.
The trial was funded by Eli Lilly, the developer of retatrutide. This relationship should be considered alongside the study’s methods, published disclosures and peer-review process.
Importantly, the study did not establish that laboratory research products sold commercially have the same composition, quality or clinical properties as the material used in the trial.
For further discussion, see What Are the Main Limitations of Current Retatrutide Research?.
Retatrutide Research Products Available in the UK
Peptide Lab Direct UK lists retatrutide laboratory research materials in several nominal strengths:
- Retatrutide 5mg Research Peptide — nominal 5mg research presentation.
- Retatrutide 10mg Research Peptide — nominal 10mg research presentation.
- Retatrutide 20mg Research Peptide — nominal 20mg research presentation.
These links provide access to laboratory research product information. They are not sources of clinical evidence, and the listed products should not be assumed to be equivalent to the material used in TRIUMPH-2.
The product strengths are nominal quantities per presentation, not the experimental treatment regimens examined in the clinical trial.
For a broader scientific overview, see Retatrutide Research: Triple-Receptor Mechanisms and Clinical Trials.
What Does TRIUMPH-2 Contribute to Retatrutide Research?
TRIUMPH-2 extends the clinical evidence for retatrutide into a population with obesity and type 2 diabetes.
Its principal contribution is controlled phase 3 evidence of substantial average body-weight reductions, accompanied by improvements in glycaemic measurements over 80 weeks.
The findings also provide important safety and tolerability data.
Further research is needed to establish longer-term outcomes, assess less common adverse events and determine how the results apply across different populations.
Research notice: This article is intended for scientific education. It does not provide medical advice, dosing recommendations or administration instructions. Clinical trial findings must not be interpreted as authorisation for human use of laboratory research products.
Leave a Reply